2027 Anti-Obesity Enhanced Pharmacy Benefit: Zepbound Single-Dose Pen No Longer Preferred

2027 Anti-Obesity Enhanced Pharmacy Benefit: Zepbound Single-Dose Pen No Longer Preferred

For: Professional and Facility Providers

For members with our Anti-Obesity Enhanced pharmacy benefit, the Zepbound single-dose pen will no longer be a preferred medication, starting Jan. 1, 2027, and upon authorization renewal.

Instead, the following drugs will be preferred:

  • Wegovy (semaglutide) injection
  • Wegovy (semaglutide) oral tablet
  • Zepbound (tirzepatide) Kwikpen

Both members and their prescribers will be notified of these changes via letter starting in late November.

Member Transition: How It Works

Members currently authorized for the Zepbound single-dose pen will also be authorized for Zepbound Kwikpen, Wegovy injection, and Wegovy oral tablet by Jan. 1, 2027. The authorization will start on Jan. 1, 2027, and end at the same time as their current Zepbound single-dose pen authorization. This allows members to access these medications without needing to submit another authorization.

Important: Members requesting Zepbound Kwikpen will need to try and fail both Wegovy AND Zepbound Kwikpen.

What do providers need to do?

Write a new prescription if your patient is changing from Zepbound single-dose pen to one of the preferred medications listed above. Zepbound Kwikpen also requires a prescription for compatible pen needles.

No Impact to Highmark’s Standard Pharmacy Benefit

This policy change does not impact members with the Anti-Obesity Standard pharmacy benefit, subject to pharmacy policy J-1389.

Why is Highmark making these changes?

Highmark regularly evaluates its prescription medication policies, including those for weight loss. We are focused on prioritizing the most clinically effective and cost-efficient weight loss medications for members, especially those with severe obesity and other obesity-related comorbidities.

In the Spotlight